Bio-Rad Laboratories Debt to Equity Ratio 2012-2026 | BIO
Current and historical debt to equity ratio values for Bio-Rad Laboratories (BIO) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Bio-Rad Laboratories debt/equity for the three months ending March 31, 2026 was 0.16.
| Bio-Rad Laboratories Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2026-03-31 | $2.94B | $6.85B | 0.43 |
| 2025-12-31 | $3.12B | $7.45B | 0.42 |
| 2025-09-30 | $2.96B | $6.74B | 0.44 |
| 2025-06-30 | $3.09B | $7.13B | 0.43 |
| 2025-03-31 | $2.85B | $6.68B | 0.43 |
| 2024-12-31 | $2.80B | $6.57B | 0.43 |
| 2024-09-30 | $3.12B | $7.49B | 0.42 |
| 2024-06-30 | $2.91B | $6.78B | 0.43 |
| 2024-03-31 | $3.56B | $9.05B | 0.39 |
| 2023-12-31 | $3.56B | $8.74B | 0.41 |
| 2023-09-30 | $3.48B | $8.42B | 0.41 |
| 2023-06-30 | $3.53B | $8.45B | 0.42 |
| 2023-03-31 | $3.90B | $9.76B | 0.40 |
| 2022-12-31 | $3.89B | $9.62B | 0.40 |
| 2022-09-30 | $3.61B | $8.45B | 0.43 |
| 2022-06-30 | $3.76B | $8.92B | 0.42 |
| 2022-03-31 | $4.19B | $10.18B | 0.41 |
| 2021-12-31 | $4.11B | $13.69B | 0.30 |
| 2021-09-30 | $4.62B | $15.33B | 0.30 |
| 2021-06-30 | $3.52B | $11.60B | 0.30 |
| 2021-03-31 | $3.32B | $10.61B | 0.31 |
| 2020-12-31 | $3.09B | $9.88B | 0.31 |
| 2020-09-30 | $3.20B | $8.83B | 0.36 |
| 2020-06-30 | $2.74B | $7.35B | 0.37 |
| 2020-03-31 | $2.39B | $6.29B | 0.38 |
| 2019-12-31 | $2.25B | $5.76B | 0.39 |
| 2019-09-30 | $2.05B | $5.13B | 0.40 |
| 2019-06-30 | $2.16B | $5.49B | 0.39 |
| 2019-03-31 | $2.00B | $4.86B | 0.41 |
| 2018-12-31 | $1.59B | $4.02B | 0.40 |
| 2018-09-30 | $1.82B | $4.90B | 0.37 |
| 2018-06-30 | $1.75B | $4.64B | 0.38 |
| 2018-03-31 | $1.73B | $4.49B | 0.39 |
| 2017-12-31 | $1.34B | $2.93B | 0.46 |
| 2017-09-30 | $1.34B | $2.85B | 0.47 |
| 2017-06-30 | $1.33B | $2.81B | 0.47 |
| 2017-03-31 | $1.25B | $2.71B | 0.46 |
| 2016-12-31 | $1.27B | $2.58B | 0.49 |
| 2016-09-30 | $1.32B | $2.70B | 0.49 |
| 2016-06-30 | $1.26B | $2.62B | 0.48 |
| 2016-03-31 | $1.21B | $2.54B | 0.48 |
| 2015-12-31 | $1.22B | $2.49B | 0.49 |
| 2015-09-30 | $1.24B | $2.43B | 0.51 |
| 2015-06-30 | $1.17B | $2.36B | 0.49 |
| 2015-03-31 | $1.13B | $2.20B | 0.51 |
| 2014-12-31 | $1.16B | $2.19B | 0.53 |
| 2014-09-30 | $1.21B | $2.18B | 0.56 |
| 2014-06-30 | $1.22B | $2.25B | 0.54 |
| 2014-03-31 | $1.21B | $2.23B | 0.54 |
| 2013-12-31 | $1.20B | $2.19B | 0.55 |
| 2013-09-30 | $1.16B | $2.12B | 0.54 |
| 2013-06-30 | $1.41B | $2.07B | 0.68 |
| 2013-03-31 | $1.43B | $2.03B | 0.70 |
| 2012-12-31 | $1.43B | $2.02B | 0.71 |
| 2012-09-30 | $1.37B | $1.94B | 0.71 |
| 2012-06-30 | $1.32B | $1.85B | 0.71 |
| 2012-03-31 | $1.35B | $1.84B | 0.73 |
| 2011-12-31 | $1.35B | $1.74B | 0.78 |
| 2011-09-30 | $1.28B | $1.69B | 0.75 |
| 2011-06-30 | $1.32B | $1.73B | 0.76 |
| 2011-03-31 | $1.30B | $1.61B | 0.80 |
| 2010-12-31 | $1.52B | $1.54B | 0.99 |
| 2010-09-30 | $1.25B | $1.43B | 0.88 |
| 2010-06-30 | $1.22B | $1.30B | 0.94 |
| 2010-03-31 | $1.25B | $1.30B | 0.96 |
| 2009-12-31 | $1.26B | $1.28B | 0.98 |
| 2009-09-30 | $1.25B | $1.23B | 1.02 |
| 2009-06-30 | $1.22B | $1.13B | 1.08 |
| 2009-03-31 | $0.90B | $1.06B | 0.85 |
| 2008-12-31 | $0.97B | $1.07B | 0.90 |
| 2008-09-30 | $0.97B | $1.05B | 0.92 |
| 2008-06-30 | $0.98B | $1.12B | 0.88 |
| 2008-03-31 | $0.97B | $1.08B | 0.90 |
| 2007-12-31 | $1.00B | $0.97B | 1.03 |
| 2007-09-30 | $0.77B | $0.95B | 0.81 |
| 2007-06-30 | $0.76B | $0.90B | 0.85 |
| 2007-03-31 | $0.75B | $0.86B | 0.87 |
| 2006-12-31 | $0.78B | $0.82B | 0.95 |
| 2006-09-30 | $0.74B | $0.79B | 0.94 |
| 2006-06-30 | $0.74B | $0.76B | 0.98 |
| 2006-03-31 | $0.71B | $0.70B | 1.01 |
| 2005-12-31 | $0.77B | $0.66B | 1.17 |
| 2005-09-30 | $0.78B | $0.65B | 1.20 |
| 2005-06-30 | $0.76B | $0.63B | 1.22 |
| 2005-03-31 | $0.78B | $0.62B | 1.24 |
| 2004-12-31 | $0.78B | $0.60B | 1.30 |
| 2004-09-30 | $0.54B | $0.55B | 0.97 |
| 2004-06-30 | $0.48B | $0.55B | 0.88 |
| 2004-03-31 | $0.48B | $0.52B | 0.93 |
| 2003-12-31 | $0.50B | $0.50B | 1.00 |
| 2003-09-30 | $0.47B | $0.46B | 1.02 |
| 2003-06-30 | $0.33B | $0.45B | 0.73 |
| 2003-03-31 | $0.33B | $0.41B | 0.79 |
| 2002-12-31 | $0.34B | $0.38B | 0.88 |
| 2002-09-30 | $0.36B | $0.36B | 1.02 |
| 2002-06-30 | $0.36B | $0.34B | 1.07 |
| 2002-03-31 | $0.38B | $0.31B | 1.25 |
| 2001-12-31 | $0.40B | $0.28B | 1.41 |
| 2001-09-30 | $0.41B | $0.27B | 1.51 |
| 2001-06-30 | $0.40B | $0.26B | 1.58 |
| 2001-03-31 | $0.40B | $0.25B | 1.63 |
| 2000-12-31 | $0.40B | $0.25B | 1.64 |
| 2000-09-30 | $0.41B | $0.23B | 1.77 |
| 2000-06-30 | $0.44B | $0.22B | 1.99 |
| 2000-03-31 | $0.45B | $0.22B | 2.07 |
| 1999-12-31 | $0.45B | $0.22B | 2.04 |
| 1999-09-30 | $0.14B | $0.23B | 0.61 |
| 1999-06-30 | $0.14B | $0.23B | 0.62 |
| 1999-03-31 | $0.15B | $0.22B | 0.67 |
| 1998-12-31 | $0.15B | $0.21B | 0.71 |
| 1998-09-30 | $0.15B | $0.21B | 0.71 |
| 1998-06-30 | $0.16B | $0.21B | 0.76 |
| 1998-03-31 | $0.16B | $0.21B | 0.78 |
| 1997-12-31 | $0.16B | $0.20B | 0.79 |
| 1997-09-30 | $0.11B | $0.20B | 0.54 |
| 1997-06-30 | $0.10B | $0.19B | 0.50 |
| 1997-03-31 | $0.10B | $0.19B | 0.56 |
| 1996-12-31 | $0.10B | $0.18B | 0.55 |
| 1996-09-30 | $0.11B | $0.18B | 0.61 |
| 1996-06-30 | $0.12B | $0.17B | 0.67 |
| 1996-03-31 | $0.13B | $0.17B | 0.75 |
| 1995-12-31 | $0.13B | $0.16B | 0.82 |
| 1995-09-30 | $0.13B | $0.15B | 0.86 |
| 1995-06-30 | $0.14B | $0.15B | 0.94 |
| 1995-03-31 | $0.14B | $0.14B | 1.03 |
| 1994-12-31 | $0.13B | $0.13B | 1.03 |
| 1994-09-30 | $0.14B | $0.13B | 1.10 |
| 1994-06-30 | $0.15B | $0.12B | 1.20 |
| 1994-03-31 | $0.15B | $0.12B | 1.27 |
| 1993-12-31 | $0.15B | $0.11B | 1.36 |
| 1993-09-30 | $0.16B | $0.11B | 1.45 |
| 1993-06-30 | $0.17B | $0.11B | 1.55 |
| 1993-03-31 | $0.17B | $0.11B | 1.54 |
| 1992-12-31 | $0.17B | $0.11B | 1.55 |
| 1992-09-30 | $0.17B | $0.11B | 1.54 |
| 1992-06-30 | $0.19B | $0.11B | 1.81 |
| 1992-03-31 | $0.17B | $0.10B | 1.73 |
| 1991-12-31 | $0.16B | $0.09B | 1.79 |
| 1991-09-30 | $0.15B | $0.09B | 1.70 |
| 1991-06-30 | $0.14B | $0.09B | 1.62 |
| 1991-03-31 | $0.14B | $0.09B | 1.60 |
| 1990-12-31 | $0.13B | $0.08B | 1.63 |
| 1990-09-30 | $0.12B | $0.08B | 1.60 |
| 1990-06-30 | $0.12B | $0.08B | 1.57 |
| 1990-03-31 | $0.12B | $0.07B | 1.58 |
| 1989-12-31 | $0.12B | $0.07B | 1.68 |
| 1989-09-30 | $0.11B | $0.07B | 1.65 |
| 1989-06-30 | $0.11B | $0.06B | 1.67 |
| 1989-03-31 | $0.11B | $0.06B | 1.82 |
| 1988-12-31 | $0.10B | $0.06B | 1.61 |
| 1988-09-30 | $0.09B | $0.06B | 1.58 |
| 1988-06-30 | $0.09B | $0.06B | 1.56 |
| 1988-03-31 | $0.09B | $0.05B | 1.65 |
| 1987-12-31 | $0.08B | $0.05B | 1.63 |
| 1987-09-30 | $0.08B | $0.05B | 1.52 |
| 1987-06-30 | $0.08B | $0.05B | 1.56 |
| 1987-03-31 | $0.07B | $0.05B | 1.49 |
| 1986-12-31 | $0.06B | $0.04B | 1.35 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $7.537B | $2.583B |
| Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels outside the United States through subsidiaries which focus on sales, customer service and product distribution. The company operates through two reportable segments - Life Science segment which designs, manufactures, markets and services reagents, apparatus and instruments utilized for biological research. Clinical Diagnostics - This business markets and distributes products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians office laboratories, transfusion laboratories as well as insurance and forensic testing laboratories. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $174.688B | 19.48 |
| Stryker (SYK) | United States | $129.889B | 24.88 |
| Medtronic (MDT) | Ireland | $111.968B | 15.57 |
| EssilorLuxottica (ESLOY) | France | $107.724B | 0.00 |
| Boston Scientific (BSX) | United States | $91.831B | 20.26 |
| Medline (MDLN) | United States | $59.904B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.712B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $33.391B | 15.98 |
| ResMed (RMD) | United States | $33.341B | 22.26 |
| Agilent Technologies (A) | United States | $32.516B | 20.44 |
| Koninklijke Philips (PHG) | Netherlands | $27.260B | 16.18 |
| Terumo (TRUMY) | Japan | $19.854B | 23.21 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.025B | 11.36 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.227B | 0.00 |
| Insulet (PODD) | United States | $13.640B | 39.54 |
| Baxter (BAX) | United States | $8.854B | 7.56 |
| Sunny Optical Technology (SNPTF) | China | $8.381B | 0.00 |
| Demant (WILYY) | Denmark | $6.395B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $5.247B | 15.90 |
| Envista Holdings (NVST) | United States | $4.301B | 21.99 |
| BillionToOne (BLLN) | United States | $3.729B | 0.00 |
| DiaSorin S.p.A (DSRLF) | Italy | $3.666B | 0.00 |
| ICU Medical (ICUI) | United States | $3.141B | 20.47 |
| Prestige Consumer Healthcare (PBH) | United States | $2.676B | 12.62 |
| Haemonetics (HAE) | United States | $2.664B | 11.65 |
| LeMaitre Vascular (LMAT) | United States | $2.611B | 48.16 |
| Phibro Animal Health (PAHC) | United States | $2.347B | 20.67 |
| GN Store Nord (GNNDY) | Denmark | $2.270B | 21.90 |
| Neogen (NEOG) | United States | $2.050B | 44.86 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $2.028B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $1.794B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.654B | 32.89 |
| Curaleaf Holdings (CURLF) | Canada | $1.584B | 0.00 |
| Perrigo (PRGO) | Ireland | $1.495B | 3.96 |
| AtriCure (ATRC) | United States | $1.429B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.386B | 15.91 |
| Kestra Medical Technologies (KMTS) | United States | $1.043B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.953B | 164.50 |
| QuidelOrtho (QDEL) | United States | $0.943B | 6.53 |
| Lumexa Imaging Holdings (LMRI) | United States | $0.896B | 0.00 |
| InMode (INMD) | Israel | $0.857B | 9.40 |
| Omeros (OMER) | United States | $0.827B | 6.49 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.789B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.766B | 0.00 |
| CeriBell (CBLL) | United States | $0.683B | 0.00 |
| Brainsway (BWAY) | Israel | $0.546B | 55.68 |
| Valneva SE (VALN) | France | $0.532B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.468B | 11.18 |
| Cresco Labs (CRLBF) | United States | $0.458B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.424B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.415B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.367B | 25.70 |
| SNDL (SNDL) | Canada | $0.366B | 0.00 |
| Cerus (CERS) | United States | $0.363B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.311B | 126.00 |
| Evolus (EOLS) | United States | $0.278B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.259B | 0.00 |
| MacroGenics (MGNX) | United States | $0.229B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Accendra Health (ACH) | United States | $0.215B | 2.96 |
| Utah Medical Products (UTMD) | United States | $0.210B | 18.94 |
| High Tide (HITI) | Canada | $0.205B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.205B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.194B | 57.17 |
| TerrAscend (TSNDF) | Canada | $0.193B | 0.00 |
| Organigram Global (OGI) | Canada | $0.191B | 0.00 |
| Apyx Medical (APYX) | United States | $0.166B | 0.00 |
| Quanterix (QTRX) | United States | $0.158B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.152B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.145B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.143B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.133B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.53 |
| Jushi Holdings (JUSHF) | United States | $0.101B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.090B | 11.73 |
| Exagen (XGN) | United States | $0.073B | 0.00 |
| Sharps Technology (STSS) | United States | $0.065B | 0.00 |
| ImmuCell (ICCC) | United States | $0.064B | 0.00 |
| Biote (BTMD) | United States | $0.063B | 3.46 |
| INLIF (INLF) | China | $0.053B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.038B | 0.00 |
| Veru (VERU) | United States | $0.038B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| Nephros (NEPH) | United States | $0.032B | 26.91 |
| United-Guardian (UG) | United States | $0.030B | 14.23 |
| Bonk (BNKK) | United States | $0.021B | 0.00 |
| Jin Medical (ZJYL) | China | $0.018B | 0.00 |
| Modular Medical (MODD) | United States | $0.013B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Agape ATP (ATPC) | $0.003B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.001B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |